The estimated Net Worth of Gregory Cole Davis is at least $329 mil dollars as of 29 May 2019. Gregory Davis owns over 15,000 units of Basis Global Technologies Inc stock worth over $328,800 and over the last 7 years he sold BASI stock worth over $0. In addition, he makes $0 as Interim Chairman of the Board at Basis Global Technologies Inc.
Sign up
Gregory Davis BASI stock SEC Form 4 insiders trading
Gregory has made over 2 trades of the Basis Global Technologies Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of BASI stock worth $29,700 on 29 May 2019.
The largest trade he's ever made was buying 15,000 units of Basis Global Technologies Inc stock on 29 May 2019 worth over $29,700. On average, Gregory trades about 4,000 units every 130 days since 2017. As of 29 May 2019 he still owns at least 20,000 units of Basis Global Technologies Inc stock.
You can see the complete history of Gregory Davis stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gregory Davis biography
Dr. Gregory C. Davis Ph.D. is Interim Chairman of the Board of the Company. Dr. Davis is currently running his own consulting firm, which he founded in 2012, assisting companies with regulatory and control strategy and product development issues. In 2014, Greg joined Calibrium, LLC as Vice President of CMC, Regulatory, and Quality. Calibrium was developing novel biotheraputics for the treatment of diabetes. The company was sold to Novo Nordisk in late 2015. From 1992 to 2012, Dr. Davis held various leadership positions at Eli Lilly in Biotechnology Product Development, Global Regulatory Affairs, Global Brand Teams, and Quality. One of the highlights of his Lilly career was being COO of the Xigris Product Team. Xigris was the first biotechnology product ever approved for the treatment of severe sepsis. When Greg retired from Eli Lilly in December of 2012, he was Executive Director and Senior Principle Fellow in Global Regulatory Affairs. Dr. Davis has held numerous leadership positions within the Pharmaceutical Research and Manufacturers Association (PhRMA), the United States Pharmacopeia (USP), and the Biotechnology Industry Organization (BIO). He also served for five years as the PhRMA liaison to the International Conference on Harmonization (ICH) for Q5/Q6 Biotechnology topics. He coauthored several of the ICH guidances on registration standards for biotechnology products which are still in use today. Dr. Davis received his bachelor’s degree from Southeast Missouri State University and his Ph.D. in Analytical Chemistry from Purdue University studying under Dr. Peter Kissinger, founder of BASi.
What's Gregory Davis's mailing address?
Gregory's mailing address filed with the SEC is C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE, IN, 47906.
Insiders trading at Basis Global Technologies Inc
Over the last 21 years, insiders at Basis Global Technologies Inc have traded over $266,443 worth of Basis Global Technologies Inc stock and bought 540,162 units worth $1,698,287 . The most active insiders traders include Jacqueline M Lemke, Robert Jr. Leasure y William D Pitchford. On average, Basis Global Technologies Inc executives and independent directors trade stock every 65 days with the average trade being worth of $128,544. The most recent stock trade was executed by Beth Taylor on 5 March 2021, trading 5,000 units of BASI stock currently worth $88,500.
What does Basis Global Technologies Inc's logo look like?
Complete history of Gregory Davis stock trades at Basis Global Technologies Inc
Basis Global Technologies Inc executives and stock owners
Basis Global Technologies Inc executives and other stock owners filed with the SEC include:
-
Wendy Perrow,
Independent Director -
R. Matthew Neff,
Independent Director -
Richard Johnson,
Independent Director -
Joseph Flynn,
Chief Commercial Officer -
John Sagartz,
Chief Strategy Officer, Director -
Connie Dougherty,
Vice President - Business Development -
I.M. Grossi,
Vice President - Toxicology -
Philip Downing,
Vice President - Preclinical Services -
Andrew Alexander,
Vice President - Pharmacology and Toxicology Operations -
Michael Baim,
Vice President - Bioanalytical Operations -
Beth Taylor,
Chief Financial Officer, Vice President - Finance -
Robert Leasure,
President, Chief Executive Officer, Director -
Gregory Davis,
Interim Chairman of the Board -
Jill Blumhoff,
VP, Finance & CFO -
John P Devine,
VP--Toxicology -
James Sevall Bourdage,
VP, Bioanalytical Services -
Jacqueline M Lemke,
CFO & Vice President--Finance -
Jeffrey Potrzebowski,
VP, Finance & CFO -
John Gregory Beattie,
Chief Operating Officer -
Peterkissinger Candice B Ki...,
-
Daniel Thomas Oakley,
Chief Operating Officer -
Kimberly L Sagartz,
10% owner -
Chrysalis, Llc Sw,
10% owner -
Lori Payne,
VP Bioanalytical Services -
Larry Steven Boulet,
Director -
David W Crabb,
Director -
John B. Landis,
Director -
David L Omachinski,
Director -
Anthony S Chilton,
COO, Scientific Studies -
A. Charlene Sullivan,
Director -
Alberto F Jr Hidalgo,
VP, Bus. Development & Mrkting -
Leslie B Daniels,
Director -
Kathleen Hodges,
Vice President of Quality -
Lina L Reeves Kerner,
V.P. - Human Resources -
Richard M Shepperd,
President & Chief Exec. Off. -
Ronald E Shoup,
Chief Operating Officer -
Craig S Bruntlett,
Sr. V.P. International Sales -
Jon Brewer,
VP Sales/Marketing -
William E Baitinger,
Director -
Candice B Kissinger,
Vice President -
Margaret B Mcclure,
Dir, Pharmaceutical Lab. Div. -
Michael R Cox,
V.P. Finance, CFO -
Emilio Cordova,
V.P. of Business Development -
Edward Chait,
Executive Vice President -
Gerry Henningsen,
Director BAS Evansville -
Donnie A Evans,
Vice President Engineering -
Garyl W Doster,
Director -
Michael P Silvon,
Vice President -
Michael S Noone,
Dir. of Clinical Affairs, Balt -
William Sawyers,
Laboratory Director -
William D Pitchford,
Chief HR Officer